1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016, 66(1):7-30.
2. Le Pechoux C: Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011, 16(5):672-681.
3. Aggarwal A, Lewison G, Idir S, Peters M, Aldige C, Boerckel W, Boyle P, Trimble EL, Roe P, Sethi T et al: The State of Lung Cancer Research: A Global Analysis. J Thorac Oncol 2016, 11(7):1040-1050.
4. Cui Y, Jia J: Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol 2013, 28 Suppl 1:7-10.
5. Song C, Lv J, Liu Y, Chen JG, Ge Z, Zhu J, Dai J, Du LB, Yu C, Guo Y et al: Associations Between Hepatitis B Virus Infection and Risk of All Cancer Types. JAMA Netw Open 2019, 2(6):e195718.
6. Engels EA, Cho ER, Jee SH: Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010, 11(9):827-834.
7. Liu X, Li X, Jiang N, Lei Y, Tang LL, Chen L, Zhou GQ, Sun Y, Yue D, Guo R et al: Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: analysis of 1301 patients from an endemic area in China. cancer 2014, 120(1):68-76.
8. Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC cancer 2008, 8:115.
9. Teng CJ, Liu HT, Liu CY, Hsih CH, Pai JT, Gau JP, Liu JH, Chiou TJ, Hsu HC, Chen PM et al: Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. Clinics (Sao Paulo) 2011, 66(12):2055-2061.
10. Greene FL, Sobin LH: The TNM system: our language for cancer care. J Surg Oncol 2002, 80(3):119-120.
11. Cagle PT: Lung Carcinoma Staging Problems. Surg Pathol Clin 2010, 3(1):61-69.
12. Vielh P, Spano JP, Grenier J, Le Chevalier T, Soria JC: Molecular prognostic factors in resectable non-small cell lung cancer. Crit Rev Oncol Hematol 2005, 53(3):193-197.
13. Burke HB: Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst 2004, 96(19):1408-1409.
14. Thakur MK, Gadgeel SM: Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. Semin Respir Crit Care Med 2016, 37(5):760-770.
15. Bianconi F, Fravolini ML, Bello-Cerezo R, Minestrini M, Scialpi M, Palumbo B: Evaluation of Shape and Textural Features from CT as Prognostic Biomarkers in Non-small Cell Lung Cancer. Anticancer Res 2018, 38(4):2155-2160.
16. Matikas A, Syrigos KN, Agelaki S: Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. Clin Lung Cancer 2016, 17(6):507-516.
17. Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474.
18. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Fruh M: Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung cancer 2017, 111:176-181.
19. Lee H, Choi YH, Sung HH, Han DH, Jeon HG, Chang Jeong B, Seo SI, Jeon SS, Lee HM, Choi HY: De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery. Clin Genitourin Cancer 2017, 15(3):e379-e385.
20. Chang SJ, Hou MF, Tsai SM, Wu SH, Hou LA, Ma H, Shann TY, Tsai LY: The association between lipid profiles and breast cancer among Taiwanese women. Clin Chem Lab Med 2007, 45(9):1219-1223.
21. Deng TB, Zhang J, Zhou YZ, Li WM: The prognostic value of C-reactive protein to albumin ratio in patients with lung cancer. Medicine (Baltimore) 2018, 97(50):e13505.
22. Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H, Sharma R, Small D: The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol 2010, 17(4):52-58.
23. He X, Li JP, Liu XH, Zhang JP, Zeng QY, Chen H, Chen SL: Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients overall survival: comparison among various inflammation based factors. J Cancer 2018, 9(10):1877-1884.
24. Shiba H, Horiuchi T, Sakamoto T, Furukawa K, Shirai Y, Iida T, Fujiwara Y, Haruki K, Yanaga K: Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma. Oncol Lett 2017, 14(1):293-298.
25. Diboun I, Wernisch L, Orengo CA, Koltzenburg M: Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics 2006, 7:252.
26. Goeman JJ: L1 penalized estimation in the Cox proportional hazards model. Biom J 2010, 52(1):70-84.
27. Tibshirani R: The lasso method for variable selection in the Cox model. Stat Med 1997, 16(4):385-395.
28. Vickers AJ, Cronin AM, Elkin EB, Gonen M: Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008, 8:53.
29. Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56(2):337-344.
30. Schroder MS, Culhane AC, Quackenbush J, Haibe-Kains B: survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics 2011, 27(22):3206-3208.
31. Shim JH, Jun MJ, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC: Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg 2015, 261(5):939-946.
32. Williams S: Pearson's correlation coefficient. N Z Med J 1996, 109(1015):38.
33. Jin S, Cao S, Xu S, Wang C, Meng Q, Yu Y: Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy. Clin Respir J 2018, 12(9):2433-2440.
34. Nakagawa T, Toyazaki T, Chiba N, Ueda Y, Gotoh M: Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. Interact Cardiovasc Thorac Surg 2016, 23(4):560-566.
35. Xu S, Xi J, Jiang W, Lu S, Wang Q: Solid component and tumor size correlate with prognosis of stage IB lung adenocarcinoma. Ann Thorac Surg 2015, 99(3):961-967.
36. Wang YQ, Zhi QJ, Wang XY, Yue DS, Li K, Jiang RC: Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer. Oncol Lett 2017, 14(4):4331-4338.
37. Kim SH, Lee HW, Go SI, Lee SI, Lee GW: Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Oncotarget 2016, 7(24):36198-36206.
38. Pilling JE, Dusmet ME, Ladas G, Goldstraw P: Prognostic factors for survival after surgical palliation of malignant pleural effusion. J Thorac Oncol 2010, 5(10):1544-1550.
39. Shi H, Huang H, Pu J, Shi D, Ning Y, Dong Y, Han Y, Zarogoulidis P, Bai C: Decreased pretherapy serum apolipoprotein A-I is associated with extent of metastasis and poor prognosis of non-small-cell lung cancer. Onco Targets Ther 2018, 11:6995-7003.
40. Kim JH, Seo SW, Chung CH: What Factors Are Associated With Early Mortality in Patients Undergoing Femur Surgery for Metastatic Lung Cancer?Clin Orthop Relat Res 2018, 476(9):1815-1822.
41. Bozkaya Y, Yazici O: Prognostic significance of gamma-glutamyl transferase in patients with metastatic non-small cell lung cancer. Expert Rev Mol Diagn 2019, 19(3):267-272.
42. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C et al: Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2018, 4(3):351-357.
43. Li N, Xu M, Cai MY, Zhou F, Li CF, Wang BX, Ou W, Wang SY: Elevated serum bilirubin levels are associated with improved survival in patients with curatively resected non-small-cell lung cancer. Cancer Epidemiol 2015, 39(5):763-768.
44. Chen S, Lai Y, He Z, Li J, He X, Shen R, Ding Q, Chen H, Peng S, Liu W: Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection. J Transl Med 2018, 16(1):116.
45. Chen S, Li X, Lv H, Wen X, Ding Q, Xue N, Su H, Chen H: Prognostic Dynamic Nomogram Integrated with Inflammation-Based Factors for Non-Small Cell Lung Cancer Patients with Chronic Hepatitis B Viral Infection. Int J Biol Sci 2018, 14(13):1813-1821.
46. Moons KG, Donders AR, Steyerberg EW, Harrell FE: Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example. J Clin Epidemiol 2004, 57(12):1262-1270.
47. Srivastava S, Chen L: Comparison between the stochastic search variable selection and the least absolute shrinkage and selection operator for genome-wide association studies of rheumatoid arthritis. BMC Proc 2009, 3 Suppl 7:S21.
48. Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z, Liang C, Tian J: Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology 2016, 281(3):947-957.
49. Baek AR, Seo HJ, Lee JH, Park SW, Jang AS, Paik SH, Koh ES, Shin HK, Kim DJ: Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer. Cancer Biomark 2018, 22(1):55-62.
50. Romero-Ventosa EY, Blanco-Prieto S, Gonzalez-Pineiro AL, Rodriguez-Berrocal FJ, Pineiro-Corrales G, Paez de la Cadena M: Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. Springerplus 2015, 4:171.
51. Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, Truini A, Rijavec E, Biello F, Sini C et al: Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Int J Mol Sci 2017, 18(5).
52. Zhang Y, Zheng H, Zhan Y, Long M, Liu S, Lu J, Zang H, Fan S: Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer. Am J Cancer Res 2018, 8(12):2377-2386.